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and anxiety (RR = 4.4, P < 0.05). Seventeen percent of 
IC patients received pentosan polysulfate sodium, the only
approved oral drug indicated for IC, within the ﬁrst two months
following the initial diagnosis. Approximately half of IC patients
received no drug treatment within two months following the
diagnosis. CONCLUSIONS: IC is a costly disease associated
with increased risk of comorbidities. IC patients are commonly
untreated.
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OBJECTIVES: To evaluate evolving epoetin alfa (EPO) and 
darbepoetin alfa (DARB) dosing patterns from 2002–2004 in
patients with pre-dialysis chronic kidney disease (CKD) receiv-
ing care in nephrology clinics. METHODS: A random panel of
approximately 250 nephrologists was requested bimonthly to
review the medical records of their last two anemic pre-dialysis
CKD patients seen currently receiving an erythropoiesis-
stimulating therapy (EST). Data on patient demographics, co-
morbid conditions, CKD status, EST dose, and frequency of
administration were collected every two months to evaluate
changes over time. RESULTS: A yotal of 1585 patient charts
were reviewed from November, 2002 to May, 2004 (EPO: 1047;
DARB: 538). Patient demographics, comorbid conditions, base-
line hemoglobin, and renal function were similar between
groups. Weekly and extended (>Q2W) dosing patterns were seen
in both groups (May, 2004—EPO: QW, 62%; Q2W, 24%;
Other, 14%; DARB: QW, 32%; Q2W, 51%; Other, 19%). A
decrease in the dose only ratio (units EPO: mcg DARB) from 
276 :1 in November, 2002 (average weekly dose—EPO: 10,481
units; DARB: 38mcg) to 217 :1 (average weighted weekly dose—
EPO: 9981 units; DARB: 46mcg) in May, 2004 was observed.
The average weekly dose over the course of the study (EPO:
10,172 units; DARB: 41mcg) corresponded to weekly costs of
$113 and $164 for EPO and DARB (based on 2003 wholesale
acquisition cost), respectively. CONCLUSIONS: Increasing
DARB doses have been seen from November, 2002 through May,
2004, resulting in a lower dose only conversion ratio and greater
average weekly drug costs compared to EPO. These analyses will
assist clinicians and formulary decision makers in identifying
real-world equivalent dosing and subsequent cost of treatment
of these agents.
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OBJECTIVE: To examine levels of persistence and compliance
with long-acting tolterodine (TOL) versus immediate- or
extended-release oxybutynin (OXY-I or OXY-X) among com-
mercially-insured patients with overactive bladder (OAB).
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database on patients diagnosed with OAB who started
therapy with TOL, OXY-I, or OXY-X between January 2001
and December 2002. Medication adherence was tracked for 12
months. Persistence with medication was calculated based on the
time from the index prescription to ﬁrst discontinuation. Dis-
continuation was deﬁned as a gap in therapy exceeding 2 times
the therapy-days supplied on the previous prescription. Compli-
ance was assessed as the ratio of the total number of days sup-
plied to the number of days persistent with medication. Results
were compared between groups descriptively. Chi-square tests
were performed comparing the proportions persistent at 1, 2, 3,
and 12 months. RESULTS: A total of 15,394 TOL, 7934 OXY-
X, and 7963 OXY-I patients were available for analysis. Com-
pliance did not differ between TOL (77.4%) and OXY-X
(74.3%), but was substantially lower for OXY-I patients
(60.9%). The mean (±SD) number of days on therapy was higher
among TOL (139 ± 132) than OXY-X (115 ± 122) or OXY-I
(60 ± 85) patients. Persistence dropped more sharply over time
among OXY-I and OXY-X than among TOL patients. At 1
month, 94.1% of TOL patients were persistent, declining to
45.9% at 3 months, and 19.9% at 12 months. Among OXY-X
patients, 89.0%, 38.2%, and 13.9% were persistent after 1, 3,
and 12 months, respectively. Corresponding ﬁgures for OXY-I
patients were 65.6%, 16.6%, and 4.3%. Between-group differ-
ences (ie, OXY-X and OXY-I vs TOL respectively) were statis-
tically signiﬁcant (p values <0.0001) at each time point.
CONCLUSIONS: Although compliance was comparable among
TOL and OXY-I patients, TOL was associated with longer dura-
tion of use relative to OXY-X and OXY-I.
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OBJECTIVE: To evaluate adherence with medications used to
treat overactive bladder (OAB) in a managed care population.
METHODS: This was retrospective study performed using pre-
scription drug claims data from a managed care organization for
medications used in the treatment of OAB. The data set analyzed
contained 18-months of prescriptions claims but only members
that were newly started on an OAB medication between study
months six and 12 were included in our analysis. The adherence
indicators used in this study were the medication possession ratio
for the ﬁrst 180 days of therapy (MPR 180) and persistence on
therapy at six months. The factors inﬂuencing the MPR 180 and
persistence were evaluated using multi-factorial linear regression,
and binary logistic regression, respectively. Factors evaluated
were age, gender, type of insurance plan, and the speciﬁc OAB
medication. RESULTS: There were 489 members initiated on
OAB medications during the study period. Immediate release
oxybutynin accounted for 81.6% of OAB medications initiated.
For all OAB medications, the MPR 180 was 37.4% and persis-
tence at six-months was 31.5%. Speciﬁc OAB medication was
the only factor that was signiﬁcantly correlated with both the
MPR 180 (P < 0.001) and persistence on medications (P =
0.013). Patients initiated on extended-release oxybutynin and
extended-release tolterodine exhibited a signiﬁcantly higher
MPR 180 and were more persistent compared to patients initi-
ated on immediate-release oxybutynin. CONCLUSIONS:
Adherence to medications used to treat OAB tends to be poor.
Adherence with extended release formulations was signiﬁcantly
better than the most commonly used immediate-release generic
preparation. Poor adherence to OAB medication may hinder
members from achieving optimal therapeutic outcomes.
